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A B S T R A C T
To improve the translational predictability of treatment strategies for Huntington’s disease (HD), sensitive and
analogous cognitive outcomes are needed across HD animal models and humans. Spatial memory measures are
promising candidates because they are based on ‘visual’ or ‘non-verbal’ cognition, and are commonly tested in
both animals and humans. Here, we consider the suitability of spatial memory for strengthening translational
links between animals and humans in HD research and clinical trials. We describe ﬁndings of spatial memory
impairments in human HD and mouse models, including which aspects of spatial memory are most aﬀected and
at which time points in disease progression. We also describe the neural systems that underlie spatial memory
and link spatial memory impairments to HD neuropathology, focussing on striatal and hippocampal systems. We
provide a critical analysis of the literature in terms of the suitability of spatial memory for bridging the trans-
lational gap between species. Finally, we discuss possible neural mechanisms that might explain the spatial
memory impairments seen in HD, and their relevance to potential treatments.
1. Introduction
Cognitive impairment in Huntington’s disease (HD) is a key
symptom, for which there are no eﬀective treatments (Bates et al.,
2015). Several HD clinical trials are ongoing and potential treatments
are increasingly being targeted at ameliorating the cognitive decline
(Stout et al., 2017). Mouse models of HD are crucial components of
preclinical testing to assess the eﬀects of potential treatments (Menalled
and Chesselet, 2002). Yet, positive results from HD mouse models have
not translated to any successes in clinical trials to date (Wild and
Tabrizi, 2014). There are many reasons why preclinical results in mice
do not successfully translate to clinical trials in humans (Pankevich
et al., 2014). One reason may be that cognitive tests used in clinical
trials are misaligned with the cognitive outcomes used in the preclinical
functional assessments in mouse models (Possin et al., 2016), thus
minimizing the likelihood that what is observed in the mouse will be
seen in the human. In HD clinical trials, cognitive outcome measures
are typically selected for their sensitivity in detecting cognitive im-
pairment in patients (Stout et al., 2017), instead of maintaining ﬁdelity
with methods used in the mouse preclinical studies. Thus, an important
gap exists in clinical trial cognitive assessment methodology, which is a
lack of mechanistically-driven cognitive outcome measures that are
analogous on pre-clinical animal level.
Spatial memory tests are particularly suited for strengthening
translational links between preclinical and clinical studies. Spatial
memory can be readily tested in mice and other preclinical HD models,
as well as in humans using comparable measurement approaches.
Spatial memory includes the ability to learn the topographical conﬁg-
uration of environments, to locate objects and landmarks within en-
vironments, and to navigate from one place to another, which are
functions that have ecological importance across humans and other
animal species. Animal survival is reliant on eﬀective use of spatial
memories, such as knowing where one is, where food and water re-
sources are, and how to get to safety. Humans use their spatial memory
on a daily basis when making their way to work and back home, or
when retrieving a mobile phone from a bag (McNamara, 2013). Across
species, spatial memory relies on hippocampal and striatal networks
(Chersi and Burgess, 2015), which are signiﬁcantly aﬀected in HD
(Faria et al., 2016; Walker, 2007).
The purpose of this review is to evaluate the potential utility of
spatial memory testing for improving translational links between an-
imal models and humans, for the purpose of advancing clinical out-
comes for people with HD. We argue that spatial memory is relevant to
the cognitive phenotype of HD, and we present evidence in humans and
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animals to support this proposition. Our review starts with a description
of the neuroanatomy underlying spatial memory functions, including a
comparison between mouse and human anatomy. We then describe
evidence, from both mice and humans, illustrating that the striatum,
which is the site of the earliest and most severe pathology in HD
(Walker, 2007), is an important structure within the spatial memory
network. We then outline in more detail, and within the context of
spatial cognition, the brain pathology and cognitive phenotype of HD.
We also provide an overview of commonly used cognitive tasks in
transgenic animal models of HD. Next, we show evidence from studies
of HD, and from animal models of HD, which demonstrates spatial
memory deﬁcits that occur prior to the emergence of motor symptoms.
This evidence is particularly important from the standpoint of mea-
surement sensitivity, that is, the ability of spatial memory tests to detect
cognitive dysfunction early in the course of HD. Finally, we critically
analyse the literature in terms of the suitability of spatial memory to
bridge the gap between species in HD cognitive research and in the
assessment methodology of clinical trials. We also describe neural
systems within which spatial memory is implemented, and their re-
levance to HD.
2. Neuroanatomy of spatial memory: hippocampal and striatal
contributions
Like any complex cognitive domain, spatial memory in both the
mouse and human is mediated by a large network involving much of
the brain. Here we review two of the systems associated with spatial
memory, the hippocampal and striatal systems, both of which are also
aﬀected in HD.
Within the mesial temporal lobe, the system of structures important
for spatial memory includes the hippocampus and the adjacent para-
hippocampal, entorhinal, and perirhinal cortices. The hippocampus,
which consists of the hippocampus proper (cornu Ammonis; CA1 –
CA4) and the dentate gyrus, is a key and central component of the
spatial memory network (Kesner and Hopkins, 2006). Its long, curved
shape is present across all mammalian orders, but its internal structure
and positioning within the brain diﬀers between rodents and humans
because of variations in the migration of the hippocampus during em-
bryonic development. The human hippocampus is involved in a com-
plete rotation during development, which leaves it in a ventral position,
with CA1 in the inferior region and CA3 in the superior region (within
the coronal plane). In most mammals, the hippocampus is involved in
only partial hemispheric rotation during development. The rodent
hippocampus, for example, is in a dorsal position, and the relation of
CA1 to CA3 is thus the opposite of that found in humans (Duvernoy
et al., 2013; Kier et al., 1997; see Fig. 1). Despite diﬀerences in internal
organisation, the hippocampus is equally signiﬁcant to spatial memory
in both species (Hartley et al., 2014), as we describe below, and the
organization and connections of the hippocampus with the para-
hippocampal, entorhinal, and perirhinal cortices, are highly conserved
across brains of humans, monkeys, and rodents (Clark and Squire,
2013).
The importance of the hippocampal system to spatial memory ﬁrst
became apparent in the 1950s when Scoville and Milner (1957) re-
ported the case of patient HM who became amnesic following the re-
moval of his temporal lobes, including the hippocampi, for treatment of
intractable epilepsy. HM’s amnesia included a severe loss of spatial
memory, which was apparent immediately following his operation and
persisted for months (Scoville and Milner, 1957) and years later
(Milner, 1965). By way of example, he could not ﬁnd his way home
alone, nor could he remember where continual-used objects were kept
at home (Scoville and Milner, 1957). A subsequent key ﬁnding, in the
1970s, O’Keefe and Dostrovsky found cells that exhibit location-speciﬁc
activity in the rat’s hippocampus, and named them “place cells”
(O’Keefe and Dostrovsky, 1971). This discovery led to the hypothesis
that the hippocampus stores a cognitive map of the spatial layout of the
environment (O’Keefe and Nadel, 1978). Other types of cells that sup-
port navigation, “grid cells” and “head-direction cells”, were later found
in the rat’s entorhinal cortex, which is the main input to the hippo-
campus (Hafting et al., 2005; Taube, 1998). These cells form networks
with place cells in the hippocampus to create a comprehensive inner
global positioning system, or GPS, in the brain. Miller et al. (2015), for
example, showed that individual neurons in human entorhinal cortex
are activated at the same relative location across multiple paths during
a virtual navigation task (Miller et al., 2015).
Lesion and stimulation studies provide another line of evidence for
the importance of the hippocampus and adjacent structures in spatial
memory in both rodents (Albasser et al., 2013; Kesner et al., 2015;
Morris et al., 2012), and humans (Smith et al., 2011; Spiers et al., 2001;
Suthana et al., 2012). Typically, lesions in the hippocampal system
impair spatial memory performance on a variety of spatial memory
tasks, and stimulation enhances subsequent spatial memory perfor-
mance. Lesions in the perirhinal cortex alone, however, yield incon-
sistent results, with some studies showing impaired spatial memory
performance (Liu and Bilkey, 1998a, b, c, 1999, 2001), whereas in
others spatial memory was spared (Bussey et al., 2001; Glenn and
Mumby, 1998; Machin et al., 2002; Ramos, 2013). Thus, damage to the
perirhinal cortex may be less detrimental to spatial memory compared
to lesions of the hippocampus, or to the parahippocampal and en-
torhinal cortices.
In humans, much of what we know about the neurocognition of
memory in general, and spatial memory in particular, comes from
studies on people with temporal lobe epilepsy. Early studies indicated
lateralization of hippocampal involvement in memory. The right medial
temporal lobe was thought to be associated with recall of visual in-
formation and spatial relationships, such as visuospatial recall (for ex-
ample, Abrahams et al., 1997; Maguire et al., 1997; Milner, 1965; Pigott
and Milner, 1993; Smith and Milner, 1981, 1989). In contrast, the left
medial temporal lobe was thought to be associated with recall of verbal
material (for example, Hermann et al., 1997; Martin et al., 2002; Saling
et al., 1993). More recent ﬁndings, however, support involvement of
both the right and left medial temporal lobes in spatial memory (for
example, Canovas et al., 2011; Glikmann-Johnston et al., 2008;
Zeidman et al., 2012).
The hippocampal system implements spatial memory by yielding a
cognitive map of places and objects within the environment, in-
dependent of the actor’s body orientation, termed “allocentric” or
world-centred (Hartley et al., 2014). An allocentric perspective of the
environment supports a ﬂexible cognitive map, which is usable from
diﬀerent starting locations, or in the absence of sensory cues (Chersi
and Burgess, 2015).
In contrast to the allocentric spatial mapping within the hippocampal
system, the striatal system implements spatial processing that is ego-
centric, meaning it maps space in relation to body location, in conjunction
with sensory cues within the environment (Chersi and Burgess, 2015;
Rice et al., 2015). Rather than spatial mapping, the striatal system
supports processing of the actor’s location with relation to other objects
in the environment, for example, learning probabilistic rules, but it is
less ﬂexible than the allocentric mapping. The striatum is the largest
component of the basal ganglia, and includes the caudate nucleus,
putamen, as well as the ventral striatum, which includes the nucleus
accumbens, adjacent parts of the caudate, putamen, and basal fore-
brain. The ventral striatum receives extensive projections from the
hippocampus (Chersi and Burgess, 2015). Although all mammals have a
similar set of basal ganglia structures, neuroanatomical studies suggest
subtle diﬀerences between species (see Fig. 2 for comparison of mouse
and human striatum in HD). Relative to brain mass, the human striatum
has more neurons and is signiﬁcantly larger compared to rodents and
non-human primates (Hardman et al., 2002; Stephan, 1979; Yin et al.,
2009). The human ventral striatum has a more complex neurochemical
organisation in comparison to other species (Hardman et al., 2002),
which is thought to be related to the increase in size of striatal regions
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associated with association and limbic cortices (Holt et al., 1997).
In rodents, striatal lesions and neuropharmacological manipulations
produce signiﬁcant deﬁcits across a variety of spatial learning and
memory tasks (Block et al., 1993; Devan and White, 1999; Pooters
et al., 2016; Sargolini et al., 2003; Sutherland and Rodriguez, 1989). De
Leonbus et al. (2005) showed that for allocentric spatial information, the
dorsal striatum (caudate nucleus and putamen) was functionally dis-
tinct from the ventral striatum (nucleus accumbens), whereas the two
regions showed functional similarity in the consolidation of egocentric
spatial information. The work by Devan and White (1999) in rodents
further highlight the functional subdivisions of the dorsal striatum in
relation to spatial memory. Their ﬁndings indicated that the rodent’s
dorsomedial striatum, in contrast to the dorsolateral striatum, mediate
ﬂexible, hippocampal-dependent spatial memory. Using a water maze,
Devan and White (1999) showed that bilateral lesions to the medial
caudate-putamen impaired rodents’ learning of both cue (visible plat-
form) and spatial (submerged platform) aspects of the task, and pro-
duced a preference for the cue response. In contrast, bilateral lesions of
the lateral caudate-putamen did not aﬀect acquisition of either cue or
spatial components, but produced a preference for the spatial response.
The subdivision of the striatum into functional gradients in connectivity
and the implications for spatial cognition has been recently reviewed in
both rodent and human data (Goodroe et al., 2018). In relation to
spatial navigation, the authors suggested that the connections between
the striatum and the hippocampus, with the former being more in-
ﬂexible in terms of navigation, may enable us to make more ﬂexible
navigational responses during context-dependent spatial decision-
making. In humans, striatal involvement in spatial memory has also
been demonstrated using various imaging methods (Brown and Stern,
2014; Lisofsky et al., 2016; Woolley et al., 2013). Magnetic resonance
imaging (MRI) has indicated increased functional connectivity between
posterior hippocampus and dorsal caudate during the learning phase of
the virtual water maze task (Woolley et al., 2015), which is a human
analogue of the Morris water maze, a task used in rodents to test spatial
memory (Morris, 1981).
The literature reviewed thus far suggests the following: (i) the
hippocampal and striatal systems interact at both anatomical and
functional levels across species; (ii) this interaction appears to enable
Fig. 1. Hippocampal anatomy in mouse and human (adapted from Strange et al., 2014). A. Schematic illustrations of the orientation of the hippocampal long axis in
mouse and human. B. The hippocampus (blue) in brains of mice and humans. C. Drawings of Nissl cross sections of mouse and human hippocampi. Abbreviations: A,
anterior; C, caudal; D, dorsal; DG, dentate gyrus; L, lateral; M, medial; P, posterior; R, rostral; V, ventral.
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intact spatial memory functioning; (iii) taken together, these ﬁndings
raise the possibility that spatial memory may be used as cognitive
model system in conditions aﬀecting either the hippocampus or the
striatum. As we have shown earlier, spatial memory testing has been
extensively used for this reason in temporal lobe epilepsy studies, in
which the hippocampus is predominantly aﬀected. In contrast, in this
review, we consider spatial memory in HD because of the primary pa-
thology within the striatum.
3. Huntington’s disease: pathology and cognition
HD is an autosomal dominant neurodegenerative disorder that
causes motor, cognitive, and psychiatric disturbances, eventually
leading to dementia and death. Clinical diagnosis is based on the
combination of unequivocal chorea and a family history or genetic
conﬁrmation of risk for HD. On average, 10–15 years before clinical
diagnosis, people with the HD gene-expansion exhibit subtle cognitive
decline, psychiatric symptoms, and motor signs, in what is termed the
premanifest or preclinical stage (Bates et al., 2015). The cognitive im-
pairment is a key symptom of HD, and among the most frequently re-
ported complaint by HD patients (Stout et al., 2012; Stout et al., 2011).
HD occurs because of a pathological expansion of CAG repeat in the
huntingtin (HTT) gene on chromosome 4, which results in a mutant
huntingtin protein that contains an abnormally long polyglutamine
sequence. The mutant huntingtin protein exhibits toxic properties that
cause progressive dysfunction and neuronal death. GABA-ergic medium
spiny neurons, which account for approximately 95% of neurons within
the striatum, are particularly vulnerable to the huntingtin-induced
toxicity (Bates et al., 2015; Ross et al., 2014). The neuroanatomical
hallmark of HD is early and severe atrophy of the striatum and asso-
ciated white matter tracts (Walker, 2007), and often, to a lesser degree,
thinning of the cortical ribbon (Rosas et al., 2002). Other brain regions,
such as the globus pallidus, thalamus, and hippocampus, also undergo
early atrophy of a smaller magnitude to the striatum, and mostly after
onset of motor symptoms (Faria et al., 2016; Jernigan et al., 1991;
Younes et al., 2014). These regions have received little focus in the
literature because of the ﬁeld’s clear emphasis on the primary
pathology of HD within the striatum. Widespread brain degeneration
occurs in late stages of the disease. Our knowledge about the magnitude
of hippocampal degeneration in late stage HD is limited because post-
mortem studies are sparse and volumetry MRI studies, understandably,
include participants who can tolerate brain scanning, that is, people
with early stage HD. Some indication, however, for hippocampal de-
generation in late stage HD comes from one post-mortem study (Spargo
et al., 1993) that found lower neuronal counts in the CA1 region of the
hippocampus of nine HD cases (mean duration of disease= 9.7 years,
SD=4.5 years) compared to HIV cases and healthy controls. This dif-
ference represented a neuronal loss of 35%.
The link between brain pathology and cognitive decline in HD is not
straightforward. Striatal volume loss is detectable up to 20 years before
diagnosis (Dominguez et al., 2013; Tabrizi et al., 2009; Tabrizi et al.,
2012; Tabrizi et al., 2011; Tabrizi et al., 2013), yet cognitive decline
only becomes apparent approximately 10 years before clinical diagnosis
(Harrington et al., 2012; Paulsen, 2011; Stout et al., 2011). In the far
from onset period, at least 10 years before clinical diagnosis, compen-
satory neural processes are thought to account for the relative pre-
servation of cognitive function in the presence of signiﬁcant brain pa-
thology, however, the precise mechanism of compensation is not yet
known (Feigin et al., 2006; Georgiou-Karistianis et al., 2013; Gray et al.,
2013; Papoutsi et al., 2014; Paulsen et al., 2004; Poudel et al., 2015;
Scheller et al., 2013). Cognitive impairments in the preclinical and
early stages of the disease are relatively subtle and selective for parti-
cular cognitive functions, but in later stages when neurodegeneration is
more extensive, a wide range of cognitive domains is aﬀected. Early
cognitive symptoms typically include psychomotor slowing, executive
dysfunction, and ineﬃciencies in attention, working memory, and
emotion recognition (Paulsen, 2011; Stout et al., 2012; Stout et al.,
2011).
One of the most important advances in HD research has been the
generation of various mouse models that enable the study of early pa-
thological, molecular, cellular, and cognitive abnormalities (for review
see Menalled and Chesselet, 2002). In the next section we provide an
overview of commonly used transgenic animal models of HD.
Fig. 2. Comparison of mouse and human striatum in Huntington’s disease. Left is coronal view of a 10-month-old YAC128 mouse striatum from cryopreserved 30um
section. It was labelled with cytochrome oxidase and images were taken at 4x and stitched together on a Keyence microscope. Right is coronal MRI section from an
early-stage Huntington’s disease patient showing atrophy of the caudate and putamen, and an associated increase in size of the lateral ventricle.
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4. Overview of HD mouse models used to study cognition
Animal models of HD have been an invaluable resource for studying
the progressive behavioural and neurological decline observed in pa-
tients, and for investigating possible neuropathological processes.
Animal and cellular models are particularly valuable when they enable
the study of elements of the disease process that cannot be directly
evaluated in humans due to the need for more invasive approaches, or
because they can be used to establish preliminary evidence of safety
before ‘ﬁrst in human’ studies. Several elements of the human disease
can be usefully studied using these model systems. Naturally, models
have been an essential component in the preclinical stages of drug
development, where potential treatments can be tested for safety and
eﬃcacy to inform the translational potential for patients.
Essential to the consideration of using animal models in the pre-
clinical program, is the idea that no animal model fully recapitulate the
human disease. In fact, all eﬀective models have some elements of the
human disease that are demonstrated with good ﬁdelity, but other
elements have either poor ﬁdelity to the human condition, or are absent
entirely from that model. For example, the R6/2 and R6/1 mouse
models of HD, both of which express the N-terminal portion of human
htt, have diﬀerent number of CAG repeats and phenotypic presentation.
The R6/2 mice have highly expanded glutamine repeats (145–155),
typically surviving for 12 to 18 weeks, and developing early progressive
neurological symptoms resembling HD (at 6 to 8 weeks) (DeMarch
et al., 2008; Murphy et al., 2000). Despite the presence of the pheno-
type, however, neurodegeneration is not detectable before 14–16
weeks, which is very late in the lifespan of the R6/2 mice (Morton et al.,
2005). Thus, the R6/2 model has value for studying early deﬁcits in
synaptic physiology, cognition, and motor function (Lione et al., 1999;
Morton et al., 2005), but has limited utility for studies requiring longer
term cognitive or behavioural assessments, pharmacological screening,
and evaluations of neuronal abnormalities. In comparison, the R6/1
mice express 116 CAG repeats, typically surviving for approximately 12
months, have later age of disease onset (at 4 to 5 months), and slower
disease progression than R6/2 mice. Brain volume of R6/1 mice is
signiﬁcantly reduced by 18 weeks with striatal neuronal atrophy, but
with no neuronal loss (Ferrante, 2009).
As a service to the ﬁeld, CHDI recently released a Field Guide
(http://www.chdifoundation.org/wp-content/uploads/HD_Field_
Guide_040414.pdf) to help researchers select the appropriate animal
model for their speciﬁc purposes. The Field Guide is an essential re-
source, but focuses mainly on transgenic mouse models of HD, leaving
out many other useful models which are better described elsewhere
(e.g., transgenic rat models and toxin-induced HD models: Chang et al.,
2015; Deng et al., 2016; Fink et al., 2015; Menalled and Brunner, 2014;
Stricker-Shaver et al., 2018). Furthermore, several useful large animal
models are now being evaluated, including pig (Schuldenzucker et al.,
2017; Yan et al., 2018), sheep (Handley et al., 2016; Pﬁster et al.,
2018), and nonhuman primates (Li and Li, 2015; Yang et al., 2008).
Our review focuses on HD mouse models primarily because beha-
vioural testing in large animal models have only recently begun, and so
far included testing of basic cognitive functions such as visual dis-
crimination (McBride et al., 2016; Schuldenzucker et al., 2017). To the
best of our knowledge, the only study that assessed spatial memory in
large animal model used a nonhuman primate (Chan et al., 2014). We
begin our review with studies of spatial memory impairments in people
with HD followed by studies in mouse models of HD. We then suggest
potential neural mechanisms that may be responsible for the spatial
memory impairments seen in HD, which may be relevant for future
therapeutic interventions.
5. Spatial memory impairments in Huntington’s disease
5.1. Evidence in people with HD
Studies on spatial memory in people with HD were carried out for
two diﬀerent purposes, ﬁrst, as one of many cognitive functions inter-
rogated in HD to create the proﬁle of cognitive deﬁcits, second, to
speciﬁcally examine the possible role of striatal structures to egocentric
spatial memory. After the identiﬁcation of the CAG-expansion that
causes HD in 1993 (reviewed in Wexler et al., 2016), few studies
searched for cognitive tests or combinations of tests that can be used to
examine the eﬀects of candidate treatments (Stout et al., 2017; Stout
et al., 2014). These tests focussed on cognitive domains largely medi-
ated by striatal areas such as executive function and high-level atten-
tion (Maroof et al., 2011). Because little attention has been paid to
cognitive domains mediated by extra-striatal structures, dysfunction in
cortically-mediated cognitive domains have not been considered as
primary symptoms of HD (Papoutsi et al., 2014). Recent ﬁndings from
advanced neuroimaging methods, which show widespread neuro-
pathological changes throughout the brain that occur many years be-
fore diagnosis (Ross et al., 2014) have shifted the attention to study
cognitive domains related to other brain areas, outside of the basal
ganglia, such as parieto-occipital and temporal cortices (for example,
Johnson et al., 2015). Spatial memory is one such domain, and here we
review the evidence that spatial memory deﬁcits do occur in HD prior
to motor diagnosis and are present across a variety of spatial memory
components (Table 1).
To the best of our knowledge, the ﬁrst study to directly examine and
demonstrate spatial memory impairments in HD was published in 1971
(Potegal, 1971). In this study, HD was used as a model disease to test
the hypothesis that the caudate nucleus plays a role in egocentric
spatial localization. In the study, participants with HD had signiﬁcant
diﬃculties marking the original position of a target dot after changing
their location. Other studies followed, examining egocentric spatial
memory, with the use of variety of tasks including measures of route
learning, visual discrimination, pattern recognition, visuoconstructive
abilities, and visuoperception (Brouwers et al., 1984; Gomez-Tortosa
et al., 1996; Lawrence et al., 1996; Lawrence et al., 2000; Mohr et al.,
1991). In all of these studies, people diagnosed with HD performed
signiﬁcantly worse than controls. Some studies included patients with
Alzheimer’s disease as a comparison group to show the dissociation
between striatal- and temporal-related impairments in spatial memory
(in Table 1: Brandt et al., 2005; Brouwers et al., 1984; Hodges et al.,
1990; Lange et al., 1995).
From 1993 onward, the availability of predictive genetic testing for
HD made it possible to examine changes in spatial memory prior to the
onset of motor symptoms (termed premanifest stage). Ensuing studies
have evaluated spatial memory performance over deﬁned clinical
stages of HD. Generally, ﬁndings show that groups of people with
premanifest HD show superior egocentric spatial memory function
compared to manifest HD (Pirogovsky et al., 2015). Davis et al. (2003),
however, demonstrated that manifest HD participants were impaired on
both egocentric (hand position) and allocentric (spatial location) spatial
memory. Interestingly, a later fMRI study by Voermans et al. (2004)
found increased recruitment of the hippocampus during a route re-
cognition task in premanifest and early stage manifest HD compared to
healthy controls. The authors suggested that hippocampal activity in-
creases to compensate for declining function of the caudate nucleus in
order to maintain a similar level of function as healthy controls. Using
the Blue Velvet Arena, a virtual water maze, which is designed to dif-
ferentiate allocentric and egocentric components of spatial navigation,
HD was associated with impairment in both egocentric and allocentric
spatial representations (Majerova et al., 2012).
These ﬁndings have led to the recent hypothesis that extra-striatal
structures might also be involved in the spatial memory deﬁcits seen in
people with HD. Initial eﬀorts to test this hypothesis have commenced,
Y. Glikmann-Johnston et al. Neuroscience and Biobehavioral Reviews 98 (2019) 194–207
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and focused on structures that are core to intact spatial memory func-
tion – the hippocampus and parieto-occipital cortices. For example,
Begeti et al. (2016) used the virtual Morris water maze, which is a
human version of the original animal task that involves virtual swim-
ming in a circular pool in order to learn the location of a submerged
hidden platform relative to external cues. These authors found spatial
memory impairments on the virtual Morris water maze in manifest, but
not in premanifest HD participants, and that performance levels of the
manifest group were associated with disease burden scores [given by
(CAG-35.5) x age]. In a study using a computerised mental rotation
task, which is a visuospatial processing task, Labuschagne et al. (2016)
showed that manifest, but not premanifest HD participants, performed
worse compared to controls. Performance was associated with brain
volume loss in occipito-parietal (pre-/cuneus, calcarine, lingual), tem-
poral (posterior fusiform gyrus), and motor-related areas (supplemen-
tary motor area, precentral gyrus, and cerebellum). Degeneration of
posterior brain areas and impairments in spatial cognition in HD have
only been shown separately until recently; Labuschagne’s et al. (2016)
report is the ﬁrst that links the two in the context of HD.
In sum, promising evidence has emerged in human HD research
implicating relationships between decline in aspects of spatial cognition
and atrophy in brain regions outside of the striatal region to HD.
Evidence of non-striatal involvement has also been demonstrated in
animal models of HD, almost exclusively in mouse models. Thus far, the
only published report of spatial memory impairments in a large animal
model of HD involved a longitudinal study of a transgenic HD monkey,
rHD1 (Chan et al., 2014). Over the 2 years of the study, rHD1 showed
progressive impairments in motor and cognitive function, including
deﬁcits in spatial memory. These deﬁcits were associated with reduced
striatal and hippocampal volumes.
5.2. Evidence in HD mouse models
Research surrounding phenotypic deﬁcits in animal models of HD
has shifted in recent years, looking beyond typical motor deﬁcits, to
exploring cognitive dysfunction, learning and memory deﬁcits
(Table 2). These deﬁcits have extended past the typical striatal atrophy
and dysfunction associated with HD and studies have begun to report
pathology associated with the hippocampus as well (Bulley et al., 2012;
Giralt et al., 2011; Miguez et al., 2015; Simpson et al., 2011). Hippo-
campal-associated behavioural tasks have been extensively tested in the
transgenic HD mouse model including spatial learning tasks such as the
Morris water maze and Barnes maze, spatial working memory in the
radial arm maze, procedural learning tested in a reversal task in the
water T-maze, recognition memory using the novel object recognition
task, and delayed matching to position (DMTP) and delayed non-
matching to position (DNMTP) tasks for learning and working memory
(Table 2).
The YAC128 mouse model demonstrates impaired learning and
memory starting at 8 months of age and progressively worsening (Van
Raamsdonk et al., 2005), which has been attributed to reduced hip-
pocampal neurogenesis in the dentate gyrus, leading to a reduced
number of young neurons in the hippocampus (Simpson et al., 2011).
Changes in long-term potentiation, however, are not observed in the
early pre-symptomatic (6-months) hippocampus (Ghilan et al., 2014).
Several molecular mechanisms have been proposed to describe the
cognitive decline observed in transgenic mouse models and HD pa-
tients. These have focused on the corticostriatal pathway and suggest
altered synaptic composition, deﬁcient neurotrophic support, and
transcriptional dysregulation (Giralt et al., 2012b).
The R6/2 mouse model demonstrates progressive loss of nerve
growth factor levels (Zhang et al., 2013), and signiﬁcant reductions of
dendritic spine density and complexity in the hippocampus (Bulley
et al., 2012), suggesting that the HD mutation leads to progressive
pathology in the hippocampus in addition the striatum. However, the
striatum does appear to be the most susceptible region of the brain early
in disease progression. Using the Morris water maze, Ciamei and
Morton (2009) demonstrated that young R6/2 mice (8 weeks old)
performed the task with a cue-based escape strategy using shapes or
cues that were placed within view of the mouse to allow for spatial
recognition, which is associated with striatal function. As the disease
progressed, 12-weeks-old mice shifted to a placed-based strategy, de-
pendent on hippocampal function. Ciamei & Morton suggested that due
to functional decline of the striatum the hippocampus begins to com-
pensate for some learning based tasks (Ciamei and Morton, 2009).
It is becoming clearer that while the striatum remains the brain
region most susceptible to HD-related degeneration, the hippocampus
also plays an essential role, ﬁrst in compensation, and then in functional
deﬁcits of learning and memory.
5.3. Potential mechanisms underlying spatial memory impairments in HD
The ﬁndings we have presented thus far have been focused on
spatial memory impairments in HD from a neuroanatomical perspec-
tive, however, changes at the neuronal and neurochemical level in HD
also contribute to accounts of the spatial memory deﬁcits. Of particular
relevance are changes in levels of a key neurotrophin in HD, brain-
derived neurotrophic factor (BDNF). BDNF is involved in the formation
of the nervous system during embryonic development, postnatal brain
maturation, and regulation of synaptic transmission and neural plasti-
city that inﬂuence mechanisms of learning and memory (for review, see
Kowianski et al., 2017; Park and Poo, 2013). In the adult brain, BDNF is
highly expressed in the hippocampus, as we already showed, a brain
area critical for spatial memory (Zuccato and Cattaneo, 2007). BDNF is
also important for the survival of medium spiny neurons of the
striatum, which receives the majority of trophic BDNF support from
cortical neurons (Zuccato and Cattaneo, 2009). A loss of BDNF gene
transcription is thought to be central to the progressive pathology of HD
(Zuccato and Cattaneo, 2007, 2014). Reduced BDNF levels in mice
models of HD have been linked to impaired learning (procedural, dis-
crimination, and alternation learning), and to decreased levels of hip-
pocampal long term potentiation (LTP) (Giralt et al., 2009). In knock-in
mouse models of HD (HdhQ92, HdhQ111, CAG140), upregulating BDNF
restored deﬁcits in LTP (Lynch et al., 2007), and improved memory
performance on a novel object recognition test (Simmons et al., 2009),
thus strengthening the link between BDNF in HD neurodegeneration
and spatial memory.
The spatial memory impairments in HD could also be related to
disruption in the serotonergic system. Serotonin (5-HT) has long been
known to be involved in learning and memory (Altman and Normile,
1988). More recently, the 5-HT1A receptor subtype, which is highly
concentrated in the hippocampus, has been speciﬁcally implicated in
spatial memory (for review, see Glikmann-Johnston et al., 2015).
Generally, blockade of the 5-HT1A receptors (in knockout mouse models
or by the use of antagonists) impair spatial memory, and activation (via
agonists) ameliorates the blockade-induced spatial deﬁcits, allowing
normal performance. In HD, the serotonergic system is dysfunctional
early in the disease. Decreased 5-HT1A receptor binding in hippocampal
and cortical regions has been found in presymptomatic and sympto-
matic R6/2 mice (Yohrling et al., 2002). The number of 5-HT-con-
taining cells in the dorsal raphe nucleus, which synthesizes 5-HT, have
been found to be reduced in knock-in rats, and in postmortem human
tissue (Jahanshahi et al., 2013). Axons of the dorsal raphe innervate
almost all regions of the central nervous system, thus aﬀecting a great
variety of behaviors, such as sleep/wake cycle, food intake, sexual be-
havior, emotional state, and cognitive processes, particularly learning
and memory (Frazer and Hensler, 1994). Nevertheless, to date, treat-
ments aimed at altering 5-HT levels in people with HD have not aﬀected
cognitive function. For example, the antidepressants ﬂuoxetine (Como
et al., 1997) and citalopram (Beglinger et al., 2014), both of which are
selective serotonin reuptake inhibitors that increase levels of 5-HT, did
not aﬀect performance on a variety of cognitive tests. Importantly,
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however, spatial memory tests have not been incorporated as outcome
measures in any of the 5-HT-based treatment trials. In contrast, altered
5-HT receptors expression in the R6/1 mouse model has been asso-
ciated with depression-related behavior (Pang et al., 2009). Separate
from HD, depression has been associated with impairments in spatial
navigation and abnormal hippocampal functioning (Cornwell et al.,
2010), and dysregulation of the serotonergic system has been im-
plicated as a major factor in depression (Donaldson et al., 2013). In
premanifest HD, depression is the most common psychiatric symptom
(Pla et al., 2014). Further explanation of the mechanisms that link
Table 2
Summary of studies on spatial memory in HD mouse models.
Citation Animal model Spatial memory paradigm Results
Van Raamsdonk et al.,
2005
YAC128 mouse model. 1 AR for motoric memory
2 OF habituation test for learning
and memory
3 SWT procedural memory
4 T-S procedural learning and
memory
5 Reversal phase T-S test of
strategy shifting
6 PPI and habituation to acoustic
startle.
1 AR: YAC128 < WT controls, progressive decline from 6-mo
onward to 12-mo of age.
2 OF: YAC128 < WT in intersession habituation at 8-mo age.
3 SWT: YAC128 < WT at 8-mo of age.
4 T-S: YAC128 < WT at 8.5-mo of age.
5 Reversal swimming T-maze: YAC128 < WT at 8.5-mo of age.
6 PPI: YAC128 < WT in habituation to startle at 12-mo of age.
Nithianantharajah et al.,
2008
R6/1 mouse model, males and
females, raised in standard and
enriched environments.
1 Y-Maze
2 NORT
3 NOLT
4 BM
5 Elevated plus maze
6 Light/dark alternation test
1 Y-Maze: R6/1 < WT in novel arm exploration beginning at 12-
wks of age.
2 Novel Object Recognition: R6/1=WT at 14-wks of age.
3 Novel Object Location: R6/1 < WT at 14-wks of age.
4 Barnes maze: R6/1 < WT ﬁnding escape 12-wks of age.
Enriched R6/1 > Standard R6/1 at 12-wks of age.
5 Elevated plus maze: R6/1=WT at 12-wks of age from both
enriched and standard environments.
6 Light/dark alternation: R6/1=WT at 12-wks of age from both
enriched and standard environments.
Ciamei and Morton, 2009 R6/2 mouse model. Males only. MWM 8-week-old R6/2 mice preferentially use a cue-based (striatal) escape
strategy while 12-week-old mice use a place-based strategy
(hippocampal) to escape the maze.
Giralt et al., 2011 R6/1 and R6/2 mouse model – males
only.
1 NORT
2 T-SAT
3 MWM
1 NORT: Reduction in 12-wk old R6/1 in NOR-LTM compared to 4-
week old.
R6/2 < WT at 8-wks of age.
Treated R6/2 with PKA inhibition=WT at 8-wks of age.
2 T-SAT: R6/1 < WT in LTM.
3 MWM: R6/1 < WT in time spent in quadrant.
Giralt et al., 2012a,b HdhQ7/Q111 mouse model. 1 NORT
2 MWM
1 NORT: HdhQ7/Q111 < WT in long-term memory NORT task,
but not short-term memory at 8-mo of age.
2 MWM: HdhQ7/Q111 < WT in ﬁnding target platform.
Giralt et al., 2013 R6/1 mouse model treated with a
PDE10 inhibitor. Male only.
1 NORT
2 MWM
1 NORT: treated R6/1 > untreated R6/1 in long-term memory
NORT task.
2 MWM: treated R6/1 > untreated R6/1 in time to platform and
total platform crossings.
Rattray et al., 2013 R6/1 mouse model. Male and female. 1 T-S
2 Fear conditioning to measure
memory retention and
extinction.
1 T-S: male R6/1=WT.
Female R6/1 < WT deﬁcient at 15 weeks of age. Both male and female
R6/1 s developed an age-related deﬁcit in cue reversal learning in the
swimming T-maze.
2 Fear conditioning test: R6/1 s had a signiﬁcantly lower fear
response compared to WTs.
Southwell et al, 2013 Hu97/18, males and females. 1 NOLT
2 NORT
1 NOLT: Hu97/18 < Controls beginning at 6 mo of age.
2 NORT: Hu97/18 < Controls beginning at 9 mo of age.
Zhang et al., 2013 R6/1 mouse model infused with
neural growth factor. Males and
females.
Radial maze NGF-infused R6/1=WT following 2-week infusion of NGF.
NGF-infused R6/1 < WT following 2-week wash-out of NGF.
Miguez et al., 2015 R6/1 mouse model treated with
Fingolimod (FTY720). Males only.
1 NOLT
2 T-SAT
1 NOLT: FTY720 Treated R6/1 > untreated controls at 17-weeks
of age.
2 T-SAT: FTY720 Treated R6/1 > untreated controls at 18-weeks of
age.
Yhnell et al., 2016 HdhQ111 mouse model, males and
females
1 Delayed matching to position
(DMTP)
2 Delayed non-matching to
position (DNMTP)
Both DMTP and DNMTP tasks revealed signiﬁcant deﬁcits in reversal
learning in HdhQ111 mice.
Southwell et al., 2017 Hu128/21 mouse model, males and
females.
1 T-SAT
2 NOLT
3 NORT
1 T-SAT: Hu128/21 < Controls beginning at 4 mo of age.
2 NOLT: Hu128/21 < Controls beginning at 3 mo of age.
3 NORT: Hu128/21 < Controls biegnning at 6 mo of age.
Southwell et al., 2018 Hu97/18 HD mouse. Males and
females.
1 NOLT
2 NORT
1 NOLT: Hu97/18 mice treated at both 6-weeks and 6-mo of
age > untreated mice when assessed at 9-mo of age.
2 NORT:
Hu97/18 mice treated at 6-weeks of age > untreated controls.
Hu97/18 mice treated at 6-mo of age= untreated controls.
Abbreviations: MWM: Morris water maze; NORT: novel object recognition test; NOLT: novel object location test; T-SAT: T-maze spontaneous alternation test, OF:
open ﬁeld; AR: accelerating rotarod; FYT720: Fingolimod; ASO: antisense oligonucleotide; SWT: simple swimming task; RM: radial maze; BT: Barnes test; T-S: T-maze
swimming; PPI: prepulse inhibition; LTM: long-term memory; STM: short-term memory.
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spatial memory, the serotonergic system, and depression in HD will
enable us to identify more precise cognitive outcome measures that are
related to HD at diﬀerent levels in the testing of potential treatments.
The relationship of spatial memory with changes in BDNF levels,
and with disruptions to the serotonergic system, may have important
implications for potential treatments for HD. Restoration of BDNF levels
appears to be a more promising method (for review see Wild and
Tabrizi, 2014) than methods targeting the serotonergic system (for
example, Beglinger et al., 2014), and it is our view that incorporating
spatial memory as an outcome measure will prove to be beneﬁcial for
future trials.
6. Summary of the literature reviewed
The ﬁndings reviewed here provide substantial convergent evidence
showing that spatial memory impairment is a cognitive symptom in HD.
Since the early 1970s, ﬁndings have accumulated showing deﬁcits in
performance on a variety of spatial memory measures in people with
HD. Spatial memory deﬁcits appear to be subtle in the premanifest
stage and become more pronounced as HD progresses into and through
symptomatic stages. These spatial memory deﬁcits are associated with
the progressive pathology in the striatum and hippocampus. Research
in HD mouse models, and in one non-human primate study, show si-
milar ﬁndings, and strong evidence linking spatial memory impair-
ments to HD at the neuroanatomical and neuronal levels. Speciﬁcally,
mice that are genetically engineered to develop HD (R6/1, R6/2, YAC
128, Hdhq111, and HdhQ7/Q111) also develop deﬁcits in spatial
memory. Similar to the human data, striatal and hippocampal pa-
thology, as evident by reductions in neurogenesis, dendritic spine
density and complexity, are thought to be related to the spatial memory
deﬁcits. Restoration of hippocampal neurogenesis in the R6/1 mice is
followed by improvements in spatial memory (for example, Miguez
et al., 2015).
We have focused our review on the contributions of the striatum
and hippocampus to spatial memory in HD because both structures are
aﬀected in HD, and also play key roles in spatial memory. Early and
severe degeneration of the striatum is the hallmark neuropathological
ﬁnding in HD. The hippocampus is also aﬀected early in the course of
the disease, but to a lesser extent than the striatum. In relation to spatial
memory, the hippocampus is a key structure that facilitates allocentric
learning and memory, whereas the striatum supports egocentric-based
learning. The interplay between the striatum and the hippocampus has
been suggested to explain the nature of spatial memory impairments
seen in diﬀerent stages of HD (Ciamei and Morton, 2009; Possin et al.,
2017; Voermans et al., 2004). Essentially, in premanifest and early
stages, when striatal degeneration is well underway, the hippocampus,
which is then less aﬀected, is thought to compensate for the lost striatal-
mediated function. At this point, spatial memory is only mildly im-
paired, and learning and memory is achieved via hippocampal-depen-
dent or allocentric (world-centered) frame of reference. As HD pro-
gresses, and key spatial memory structures beyond the striatum
degenerate, signiﬁcant spatial memory impairments are observed.
7. Critical analysis: suitability of spatial memory to bridge the gap
between species in HD cognitive research and in the assessment
methodology of clinical trials
The aim of this review was to analyse the utility of the spatial
memory domain as a translational link between HD animal models and
humans in HD cognitive research and clinical trials. We have shown on
multiple and complementary levels that spatial memory has strong
potential for closing the gap between animals and humans in HD cog-
nitive research and in the eﬃcacy assessment of HD clinical trials. First,
spatial memory impairments are seen in HD and animal models of HD,
across all models that were tested, including in humans, and in HD
transgenic models of mice, rats, and monkeys (see Tables 1 and 2). In
each of these species, spatial memory impairments are signiﬁcant and
occur before the emergence of motor symptoms. Second, the spatial
memory impairments are evident across analogous animal-human
spatial memory tests, including the rodent’s MWM in Giralt et al.
(2011), and the human analogue vMWM in Begeti et al. (2016) and on
other tasks that assess the same spatial memory components. For ex-
ample, impairments in visual pattern recognition memory have been
shown in people with HD on the CANTAB pattern recognition memory
(Lawrence et al., 2000), in mice on the novel object recognition test
(Giralt et al., 2011), and in sheep on a two-choice object discrimination
task (McBride et al., 2016). Third, all species share common brain
structures and neural systems that implement spatial memory pro-
cesses, namely the hippocampus and striatum, both of which are also
relevant to HD neuropathology. These three lines of evidence support
our assertion that testing across species can be eﬀectively achieved by
using tests within the domain of spatial memory. Alignment of cogni-
tive tests probing similar neural systems across species has promise for
improving translatability from preclinical testing through to human
trials, and provides the basis for predicting eﬃcacy in clinical trials.
What type of spatial memory tasks should be used in each stage of
HD to help in the alignment of cognitive testing between people and
animal models? In the premanifest period of HD when cognitive
symptoms are either absent or very subtle, spatial memory tasks that
combine both allocentric and egocentric components, and that engage
the wider spatial memory network (Ekstrom et al., 2014), including the
striatum and the hippocampus, may be appropriate. Such tasks would
need to be multidimensional, potentially mimicking the spatial memory
demands of everyday life, which could be achieved by the use of virtual
environments. More traditional spatial memory tasks such as those used
in neuropsychological assessments can be used in the manifest stages of
HD because cognitive impairments, including those related to spatial
cognition, are obvious at this stage and can be easily picked up. For the
purpose of clinical trials, tasks of spatial navigation with aspects of
object-location memory would align well with spatial memory tasks
used in the preclinical testing of HD animal models.
8. Conclusion
The ability to test cognition in a comparable fashion in animals and
humans is particularly important for HD and other diseases caused by
trinucleotide (CAG)-repeat disorders (for example, spinocerebellar
ataxias) because of the unique therapeutic opportunities. In many of the
trinucleotide repeat diseases there is a signiﬁcant degree of overlap in
both clinical features and molecular pathology (Everett and Wood,
2004). One of the shared clinical features is disease onset. Gene carriers
have no symptoms for many years until an onset at an age that is in-
versely correlated with the number of CAG repeats (Jones et al., 2017).
In the typical adult onset HD, people appear healthy throughout
childhood and early adulthood, and then gradually develop signs and
symptoms of HD, leading to clinical (motor) diagnosis in middle age
(Stout et al., 2011). Premanifest HD is particularly valuable in terms of
ﬁnding eﬀective therapies to slow progression. Since cognitive symp-
toms in premanifest HD can be subtle, sensitive and analogous cognitive
measures in animal models and humans are needed to improve the
translational predictability of therapeutic strategies. Our review has
demonstrated that spatial memory measures have excellent potential to
identify individuals beginning to show subtle signs prior to motor di-
agnosis, and also might be suitable for HD clinical trials as sensitive
outcome measures.
For clinical trials speciﬁcally, we suggest that the implementation of
cognitive testing to assess the eﬃcacy of treatments should be ap-
proached in a strategic manner. This strategic approach should utilise a
consistent and uniform cognitive assessment that spans from the pre-
clinical program in animal models all the way to the clinical phases in
humans, taking into account the translational properties of the cogni-
tive outcome measures. This assessment methodology will ascertain
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that any diﬀerences in the cognitive results between trial phases could
not be attributed to diﬀerences in the cognitive measures themselves
used in each phase.
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